Agility, Flexibility, and Collaboration: The Three Principles That Redefined Post-Pandemic R&D

COVID-19 permanently shifted how modern R&D works. The teams winning now are the ones that move faster and stay rigorous by pairing open collaboration with automation, structured data, and AI-assisted decision-making.

Key Takeaways:

• ​COVID-era urgency made agility (AI + faster learning cycles) the new baseline for R&D.
• ​Flexibility increased: modality innovation and more adaptive trial approaches moved from “exceptions” to standard tools.
• ​Collaboration scaled through open data and public-private models, raising expectations for how quickly science should move.

The New Normal

Five years have passed since COVID-19 was declared a global pandemic, marking the official onset of a healthcare crisis that has claimed more than seven million lives and whose impact is still felt today. Early efforts to contain the evasive and evolving novel SARS-CoV-2 virus demanded unprecedented synergy between nations, healthcare agencies, and industry innovators, making the COVID-19 pandemic a pivotal moment in history, not just for its horrific impact on lives, but also for the way it changed modern drug discovery. Agility, flexibility, and collaboration were paramount to the world’s COVID-19 response, and these key tenets are likewise essential to both driving progress against other hard-to-treat diseases and preparing for future public health emergencies. The pandemic response set a new standard for how science, and scientists, should work. The “new normal” demands deeper collaboration and strategic use of data, automation, and AI to deliver rapid innovation.

Principles of Post-Pandemic R&D

COVID-19 disrupted traditional R&D paradigms, necessitating teams to become more agile, flexible, and collaborative. Saving lives meant rewriting traditional timelines, sharing data for the greater good, and building off established knowledge to rapidly deliver breakthroughs. The fundamental changes catalyzed by COVID-19 have persisted, helping drive progress across broad areas of science.

Agility: Working faster by working smarter

Speed is critical in curbing a public health crisis. But COVID-19 presented a novel virus with no existing vaccines or treatments. A rapid response necessitated turning the traditional drug development cycle on its head. The world needed a breakthrough and it needed it quickly. Science delivered. But how?

AI-aided R&D

Building off established knowledge and leveraging advanced technologies, like AI, were key to quickly delivering COVID-19 breakthroughs. For example, AI-based protein modeling helped researchers quickly identify treatment targets, and machine learning was used to accelerate clinical trial data analysis. Since COVID-19, innovators are increasingly looking for ways to strategically integrate AI into their R&D workflows in order to reduce timelines and manage costs across the board. AI is being leveraged from the earliest days of discovery, such as to model proteins and molecular interactions, optimize new candidates, and guide drug repurposing efforts, into later phases of development, where it can aid in efforts such as clinical trial optimization, data processing, and drug formulation.

Adaptive Accelerated Trials

Breaking the mold of traditional clinical trial design was essential when evaluating vaccine candidates that were desperately needed to curb the pandemic. Accelerated trial phases and adaptive designs with interim analysis helped researchers quickly uncover what was working, and what wasn’t, so that they could get the most effective and safe candidates into use in record time. Since the pandemic, adaptive trial design software, which can help inform decisions around efficacy and futility boundaries, dosing, eligibility, and sample size, has increasingly been regarded as an innovative and effective aid in designing trials, particularly trials for drugs targeting hard-to-treat conditions, such as cancer, Ebola, Alzheimer's disease, and more.

Flexibility: Driving change by embracing the unconventional

The early days of the pandemic were riddled with questions. Where did the virus originate? How did it spread? Who was most at risk? How could it be prevented and treated? Amongst the many unknowns, one thing was certain—SARS-CoV-2 was deadly and spreading rapidly. Curbing a pandemic fueled by a novel, evolving virus demanded flexible and unconventional approaches, and both researchers and regulators rose to the occasion.

Non-traditional Modalities

With time not on their side, researchers moved away from lengthy, traditional vaccine development and instead pursued mRNA vaccines by leveraging existing mRNA platforms. The miraculous turnaround of the COVID-19 vaccines comes on the coattails of platforms that were developed over the course of 20 years. What makes these platforms so unique is their flexibility and adaptability. Researchers were able to build off decades of work on mRNA vaccines and quickly adapt solutions for COVID-19. The success of the COVID-19 vaccines has fueled interest in broader use of mRNA vaccines, such as for personalized immunotherapy, as well other alternative vaccine platforms, such as those based on adenovirus-vectors and DNA Mabs, which aim to likewise serve as flexible immunization options for conditions such as influenza, Ebola, HIV, malaria, and more. These efforts reflect an even larger research trend of embracing flexibility within the world of drug discovery, most notably via a multimodal approach to R&D. Innovators are looking to flexibly address hard to reach targets through the best means possible, whether that be small molecules, biologics, conjugates, and as such, they need their R&D tools to support this unprecedented degree of research diversity and flexibility.

Regulatory Flexibility

Also essential to the rapid delivery of COVID-19 vaccines was regulatory flexibility, from rolling submissions to real-time reviews to emergency authorizations. These COVID-19 considerations, which sped up processes without cutting corners, can now help inform process adjustments in other high-need circumstances, from oncology, to rare disease, to emerging global health threats.

Collaboration: Advancing science by working together

As COVID-19 spread, the world began to feel smaller, not only because we were holed away in lockdown, but because others in faraway places were experiencing the same devastation and working against the same threat. This united front translated into the world science. Collaboration flourished, with the understanding that breakthroughs happen faster when working together. From remote work and cloud-based collaboration, to open data sharing, to unique partnerships, COVID-19 shifted how science is shared. This has since reshaped the industry’s approach to collaborative R&D.

Open Data

During the pandemic, we witnessed an unprecedented level of open-source work, with data about the virus and potential treatments widely shared in hopes of speeding up drug discovery. COVID Moonshot, for example, saw cross-discipline scientists worldwide collaborating on the development of antiviral candidates to combat COVID-19. The distributed computing initiative, Folding@home, enabled those researchers to band together their computing resources to power simulations to study proteins and drug targets. Another unique initiative, Project Discovery, enlisted the help of online gamers to analyze huge volumes of flow cytometry results data, not only helping researchers better understand how the human immune system responds to COVID-19, but also letting them collect training data for AI models. These sorts of collaborative scientific initiatives have continued to gain traction in the post-pandemic era. For example, in late 2024, Google DeepMind’s AlphaFold 3—an AI program for predicting protein structures as well as modeling interactions between proteins, DNA, RNA, and small molecules—was made open source to academic researchers. This will help researchers more quickly grow their understanding of biological targets and potential drug candidates, which ultimately holds promise to help transform drug discovery and reduce costs across therapeutic areas.

Public-Private Collaboration

A key takeaway from the pandemic was that expanded cooperation across pharma, biotech, and government agencies is needed to tackle global health challenges. This ideal was exemplified by ACTIV. Spearheaded by the US National Institutes for Health (NIH), ACTIV, or Accelerating COVID-19 Therapeutic Interventions and Vaccines, was a public-private collaboration that aimed to accelerate the development of COVID-19 vaccines and treatments by aligning goals and sharing resources. Similar collaborative work continues today, with hopes of preparing for future pandemics. The Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness Network (ReVAMPP), is bringing together researchers, public health officials, and pharmaceutical companies to explore the adaptability of mRNA and monoclonal antibody technologies for other high-priority virus families, including Flaviviridae, Paramyxoviridae, Picornaviridae, Togaviridae, Arenaviridae, Hantaviridae, Nairoviridae, Phenuiviridae, and Peribunyaviridae. But, these types of collaborative efforts aren’t limited to pandemic preparedness. We are seeing collaborations across wide-ranging areas. For example, OneHealthTrust is leading a number of initiatives to tackle another global health threat: antimicrobial resistance. And, in the area of oncology, Partnership for Accelerating Cancer Therapies (PACT) is bringing together public and private organizations to help advance immune therapies for cancer.

Dotmatics: Supporting the New Normal in R&D

French philosopher Jean de la Bruyere is noted as saying, “Out of difficulties grow miracles.” But curbing COVID-19 was no miracle. The remarkable breakthroughs we saw were the work of dedicated experts working together to leverage innovative approaches to science. In the end, the typical decade-long vaccine development timeline was collapsed into less than a year, illuminating the great impact that modern technologies, flexible approaches, and collaboration can have on R&D.

COVID-19 didn’t just push the boundaries of science—it rewired how research happens. In the post-pandemic research world, AI-driven tools, automation, cloud-based collaboration, and multimodal discovery have become foundational to R&D, making the process faster, more efficient, and more cost-effective. At Dotmatics, we’re supporting this new norm with our groundbreaking Luma R&D platform, which provides enterprise-level tools for integrating and analyzing multimodal data, accelerating discoveries and workflows with AI and automation, and seamlessly collaborating in the cloud.